Niagara P.A. Dust en es it fr

Niagara P.A. Dust Brand names, Niagara P.A. Dust Analogs

Niagara P.A. Dust Brand Names Mixture

  • No information avaliable

Niagara P.A. Dust Chemical_Formula

C10H14N2

Niagara P.A. Dust RX_link

http://www.rxlist.com/cgi/generic2/nicotini.htm

Niagara P.A. Dust fda sheet

Niagara_P.A._Dust FDA

Niagara P.A. Dust msds (material safety sheet)

Niagara_P.A._Dust MSDS

Niagara P.A. Dust Synthesis Reference

Pinner, Ber. 26, 294 (1893)

Niagara P.A. Dust Molecular Weight

162.232 g/mol

Niagara P.A. Dust Melting Point

-79 oC

Niagara P.A. Dust H2O Solubility

1 g/mL

Niagara P.A. Dust State

Liquid

Niagara P.A. Dust LogP

1.305

Niagara P.A. Dust Dosage Forms

Gum; Inhaler; Patch

Niagara P.A. Dust Indication

For the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.

Niagara P.A. Dust Pharmacology

Nicotine, the primary alkaloid in tobacco products binds stereo-selectively to nicotinic-cholinergic receptors on autonomic ganglia, the adrenal medulla, neuromuscular junctions and in the brain. Nicotine exerts two effects, a stimulant effect exerted at the locus ceruleus and a reward effect in the limbic system. Itranvenous administration of nicotine causes release of acetylcholine, norepinephrine, dopamine, serotonine, vasopressin, beta-endorphin and ACTH. Nicotine is a highly addictive substance. Nicotine also induces peripheral vasoconstriction, tachycardia and elevated blood pressure. Nicotine inhalers and patches are used to treat smoking withdrawl syndrome. Nicotine is classified as a stimulant of autonomic ganglia.

Niagara P.A. Dust Absorption

Absorption of nicotine through the buccal mucosa is relatively slow and the high and rapid rise followed by the decline in nicotine arterial plasma concentrations seen with cigarette smoking are not achieved with the inhaler. About 10% of absorbed nicotine is excreted unchanged in urine.

Niagara P.A. Dust side effects and Toxicity

Symptoms of overdose include nausea, abdominal pain, vomiting, diarrhea, diaphoresis, flushing, dizziness, disturbed hearing and vision, confusion, weakness, palpitations, altered respiration and hypotension. LD50= 24 mg/kg (orally in mice).

Niagara P.A. Dust Patient Information

A patient information sheet is included in the package of NICOTROL Inhaler cartridges dispensed to the patient. Patients should be encouraged to read the information sheet carefully and to ask their physician and pharmacist about the proper use of the product .

Patients must be advised to keep both used and unused cartridges out of the reach of children and pets.

Niagara P.A. Dust Organisms Affected

Humans and other mammals